Compare TRAK & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRAK | MOLN |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 154.2M |
| IPO Year | 1996 | 2021 |
| Metric | TRAK | MOLN |
|---|---|---|
| Price | $8.64 | $3.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 51.4K | 5.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $21,007,076.00 | N/A |
| Revenue This Year | $6.61 | N/A |
| Revenue Next Year | $10.04 | $374.07 |
| P/E Ratio | $30.86 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $6.94 | $3.46 |
| 52 Week High | $18.05 | $5.36 |
| Indicator | TRAK | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 48.77 |
| Support Level | $8.78 | $3.65 |
| Resistance Level | $9.09 | $3.96 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 74.82 | 53.85 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.